Aurinia Pharmaceuticals AUPH Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's deferred revenue?
- Aurinia Pharmaceuticals (AUPH) reported deferred revenue of $5.04M in Q1 2026.
- How has Aurinia Pharmaceuticals's deferred revenue changed year-over-year?
- Aurinia Pharmaceuticals's deferred revenue increased by 9.6% year-over-year, from $4.59M to $5.04M.
- What is the long-term trend for Aurinia Pharmaceuticals's deferred revenue?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's deferred revenue has grown at a 110.4% compound annual growth rate (CAGR), from $190K to $3.72M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.